Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XRTX
XORTX THERAPEUTICS INC.
NASDAQ
$2.34
▼ DOWN 4.38% (-0.11)

KEY STATISTICS

Market Cap$651.11 K
52w High$7.05
52w Low$1.73
Dividend Yield0.40%
FrequencyQuarterly
P/E-0.86
Volume22.04K
Shares Out.278.49K

COMPANY

LEADERSHIP

Allen Warren Davidoff
CHIEF EXECUTIVE
Allen Warren Davidoff

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 23, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
2

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2026-04-06Reverse1:5
2026-03-27Reverse1:5
2023-11-14Reverse1:9
2023-11-10Reverse1:9
2021-09-23Reverse1:12

PRICE

$2.34 ▼ DOWN 4.38% (−$0.11)
OVERLAYS
$2.28$2.32$2.36$2.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.34

About XORTX Therapeutics Inc.

https://www.xortx.com ↗

XORTX Therapeutics Inc. is a Vancouver-based biopharmaceutical company developing therapies for kidney diseases, diabetes, and COVID-19-related conditions, including XRx-008, XRx-101, and XRx-221.

INDUSTRY

Biotechnology

A PRODUCT XORTX THERAPEUTICS INC. IS KNOWN FOR

XRx-026 (XORLO™)
XRx-026 (XORLO™)

XORTX's lead product is a proprietary oral oxypurinol formulation for gout patients intolerant to allopurinol, with a planned NDA filing in 2026, making it their most advanced and near-term market-ready candidate.

COMPETITORS

COMPETITOR
ABBV COMPARE
PROK COMPARE
REGN COMPARE
TVTX COMPARE
VRTX COMPARE

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

SECTORS PEERS

PEERPRICE
VRAX$2.82COMPARE
LEXX$10.35COMPARE
GTBP$0.30COMPARE
MLEC$6.80COMPARE
ELAB$5.31COMPARE
ATXI$0.45COMPARE
NCEL$3.19COMPARE
DRMA$1.34COMPARE